Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 1999

View Archived Issues

Oral interferon to enter human trials for MS

Orion signs licensing agreement with R.P. Scherer for Zydis apomorphine

Clinical study of La Jolla's lupus drug expanded to Europe and Canada

LeukoSite and Medarex expand HuMab-Mouse licensing agreement

MedImmune and Ixsys form alliance for monoclonal antibody development

Onyx and Bayer select lead ras-inhibiting compound

Emisphere Technologies updates oral heparin development program

ImmunoGen discusses progress of tumor-activated prodrugs

Reticulose inhibits CCR5 receptor

Rosetta completes merger with Acacia

New MMP and/or TNF production inhibitors developed by Pfizer research group

ADIR patents new ellipticine/olivacine derivatives with excellent antitumor activity

AHP describes new dopamine autoreceptor agonists in patent literature

Agents for diabetes, impotence, lipid and cardiovascular disorders from Fujisawa

Cysteine protease-inhibitory peptides disclosed by Takeda

Naturally occurring inhibitors of cathepsins discovered at Sankyo

Novel therapy for HIV/AIDS to enter clinical trials in the U.S.

Favorable phase I results reported for GT-2331 as single doses

Rebetol combination therapy recommended for approval in E.U.

Chirocaine considered approvable by FDA, rights return to Chiroscience

German launch announced for Merck's migraine drug

SuperGen files sNDA for Nipent in mature T-cell malignancies

New merger in the making: Gilead and NeXstar

HMN-1108: new small-molecule compound specific for nNOS

Betathine approved for accelerated phase I/II trials in Canada

Corvas reacquires rights to injectable anticoagulant from Schering-Plough

Inodilating agents available for licensing from BTG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...